DEF: Jasper Therapeutics Seeks Stockholder Approval for Reverse Stock Split and Share Increase

Jasper Therapeutics is holding a special meeting on September 30, 2026, to vote on a reverse stock split and an increase in authorized shares, primarily to regain Nasdaq compliance and facilitate future corporate needs.

Summary

• Jasper Therapeutics is convening a special meeting of stockholders on September 30, 2026, to vote on two key proposals.
• The first proposal is to approve a reverse stock split of the Company's common stock at a ratio between 1-for-15 and 1-for-35, at the Board's discretion, to be effective by December 31, 2026.
• This reverse stock split is intended to address the company's non-compliance with Nasdaq's minimum bid price requirement of $1.00 per share, as the stock closed at $0.6864 on September 3, 2026.
• The second proposal is to increase the total number of authorized shares of common stock from 490,000,000 to 675,000,000.
• This increase is necessary to accommodate the conversion of preferred stock issued in connection with the acquisition of Kira Pharmaceuticals and to provide flexibility for future financing and strategic initiatives.
• A third proposal allows for the adjournment of the meeting if necessary to solicit additional proxies.
• The Board of Directors recommends voting 'FOR' all three proposals.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the company's need to implement a reverse stock split to avoid delisting from Nasdaq, coupled with a significant increase in authorized shares which could lead to future dilution.

Positives

• The company is proactively addressing the Nasdaq minimum bid price deficiency through a potential reverse stock split.
• The proposed increase in authorized shares aims to provide future flexibility for capital raising, acquisitions, and strategic partnerships.
• The virtual meeting format is intended to provide expanded access to stockholders and align with sustainability goals.

Negatives

• The company is at risk of delisting from the Nasdaq Capital Market if it fails to regain compliance with the minimum $1.00 bid price requirement by November 30, 2026.
• The reverse stock split may not be successful in increasing the stock price or sustaining it above the Nasdaq minimum requirement.
• The increase in authorized shares, if fully utilized, could lead to significant dilution for existing stockholders.
• The company has not yet regained compliance with the minimum bid price requirement since receiving the notice on June 3, 2026.

Risks

• Risk of delisting from the Nasdaq Capital Market if the minimum bid price requirement is not met by November 30, 2026.
• The reverse stock split may not achieve its intended effect of increasing and sustaining the stock price above $1.00.
• Potential for increased trading costs for stockholders who own less than 100 shares after the reverse stock split.
• The market may view the reverse stock split negatively, potentially impacting the stock price.
• Future issuances of additional authorized shares could dilute existing stockholders' ownership interests.
• The cash payment for fractional shares resulting from the reverse stock split may trigger taxable events for stockholders.

Future Outlook

The company is seeking approval for a reverse stock split and an increase in authorized shares to maintain its Nasdaq listing and provide flexibility for future corporate actions, including potential capital raises and acquisitions.

Management Comments

• The Board believes that maintaining our listing on the Nasdaq Capital Market provides a broader market for the Common Stock and facilitates the use of the Common Stock in financing and other transactions.
• We expect the Reverse Stock Split, if effected, to facilitate the continuation of such listing.
• The Board believes that the limited number of currently authorized but unissued and unreserved shares of Common Stock is insufficient to cover the conversion of the issued and outstanding shares of Preferred Stock and may restrict our ability to respond to our business needs and opportunities.
• The availability of additional shares of Common Stock for issuance will afford us flexibility by assuring that there will be sufficient authorized but unissued shares of Common Stock for business and financial purposes in the future.

Industry Context

StockSavvy.ai notes that reverse stock splits are often implemented by companies facing delisting threats due to low stock prices. The concurrent increase in authorized shares is a common strategy to ensure sufficient capital and flexibility for growth, especially after an acquisition like the one with Kira Pharmaceuticals.

Stakeholder Impact

• Shareholders may experience a significant reduction in the number of shares they hold due to the reverse stock split, though their percentage ownership should remain the same unless fractional shares are cashed out.
• Potential for increased trading costs for shareholders holding less than 100 shares post-split.
• Future issuances of stock could dilute existing shareholders' ownership.
• Employees holding stock options or awards will see adjustments to their grants.
• The company's ability to attract and retain qualified employees could be impacted by delisting or a reduced stock price.

Next Steps

• Stockholders to vote on the Reverse Stock Split Proposal, Authorized Share Increase Proposal, and Adjournment Proposal at the Special Meeting on September 30, 2026.
• If approved, the Board of Directors will determine whether to effect the reverse stock split and at what ratio, up to December 31, 2026.
• If approved, the Authorized Shares Amendment will become effective upon filing with the Delaware Secretary of State.
• The company will file a Form 8-K with the SEC to disclose preliminary voting results within four business days after the Special Meeting.

Key Dates

Recommendation

The company is facing significant challenges with Nasdaq compliance, necessitating a reverse stock split. While the increase in authorized shares provides future flexibility, the immediate concern is the potential delisting and the uncertainty surrounding the effectiveness of the reverse split. The acquisition of Kira Pharmaceuticals adds a layer of complexity and potential upside, but the current situation warrants a cautious 'hold' stance until the company demonstrates sustained compliance and successful integration.

Keywords

reverse stock split, authorized shares, Nasdaq compliance, stockholder meeting, Kira Pharmaceuticals, certificate of incorporation, common stock, preferred stock